Fluad & RapivabRUDER FINN RFP RESPONSE TO SEQIRUS

March 13, 2017

THANK YOU FOR THE OPPORTUNITY to participate in this RFP and share our capabilities with you. We hope our response continues to excite you about Ruder Finn, namely, how we work—highly collaborative and results-oriented—and the clients with which we engage.

In choosing Ruder Finn, you will be bringing a rich history of highly relevant, specialized expertise from our global healthcare, digital and creative teams responsible for some of the industry’s most recognized disease & product awareness campaigns. We are proud of the distinction, which is due largely to the collaborative and candid partnerships we enjoy with our clients.

When describing our approach, we hope you will understand how the power behind successful communications marketing comes from the collaborative efforts of many who rally around a great idea, a strong creative story, and meaningful objectives. We create transformational movements that bring people together and prompt action.

Since our founding in 1948, we have assisted our clients to effectively inform and frame healthcare agendas. We have proven time and again that we can successfully manage all aspects of complex and multifaceted communications programs that deliver meaningful results. And below are just a few of the best-in-class advantages we bring you:

• We know Seqirus and understand how you operate externally with stakeholders and internally among employees. We are currently responsible for Fluad and Rapivab product and disease education communications.

• A dedicated healthcare media relations team that brings demonstrated expertise in delivering agenda-setting broadcast, print and online media placements based upon our personal relationships with journalists.

• An unique approach focusing on creativity and innovation. We’re constantly exploring new ways we can effectively enhance the connection between consumers and the causes we want them to adopt. Whether it is creating a popular comic book series with DC Comics for children with a rare genetic disorder to leveraging Michael J. Fox’s return to TV to spark meaningful dialogue on Parkinson’s and progress toward a cure -- we never stop thinking for our partners.

We believe the same is possible in a continued partnership with Seqirus. We look forward to continuing this conversation.

Sincerely,

SALLY ANN BARTONExecutive Vice President, U.S. Healthcare Practice Head

2

Table of contents

• About Ruder Finn

• Landscape Analysis - What We Know

• Our Approach for FLUAD & RAPIVAB

• Timeline & Budget

• Your Ruder Finn Team

• Case Studies & Capabilities

3

The assignment in your words

4

• Raise awareness of FLUAD through the implementation of an integrated communications plan to help elevate discussions externally and internally to:- Drive demand for FLUAD among adults aged 65+- Strengthen awareness of FLUAD among HCPs (IM, PA and NPs)

• Strengthen awareness of Rapivab as the IV therapy for influenza in the hospital setting targeting hospital pharmacists, emergency medicine physicians and infectious disease physicians

Traditional & Social Media Strategy

Measurable Metrics

Disease Awareness HCP / Pharmacy Engagement

THE ASKS

PROJECT OUTPUTS

YOUR TEAM

Your team

6

David BrooksDigital & Social

Shannon O’BrienAccount Executive

Sally Ann BartonStrategy & Issues

Tom VickeryTeam Lead

Randi KahnVice President

Mary CoyleMedia Strategist

Patrick BurseyAccount Executive

Michael Schubert Chief Innovation Director

TRANSFORMATIONIS OUR BUSINESS

Ruder Finn is focused on helping companies and institutions transform the way they do business, go to market and communicate

with the people that matter most.

About Ruder Finn

7

Seqirus and Ruder FinnFamiliarity with business strategy, management and priority areas across the organization

8

Professional Awareness• Conducted SERMO initiative

to support Rapivab- KOL post- Poll- Banner ad

• Reached 1,613 ED, ID physicians, garnered over 2,405 views

• Media engagement featuring interviews with Dr. LoVecchio

CSL Acquisition, Seqirus Launch • Prepared, executed global, US

external and internal communications: Pre-close, transition close

- Messages, SBSs, Q&As- Press releases- Customer letters- Regional internal

communications- Internal communications

from top executives• Media engagement

Consumer Education• Launched stream of media

activities over 2 flu seasons featuring pharmacist spokesperson Kim Tran; cascade of brand-supportive messages reaches 57M+ in key markets

Issues, Data Communications• Developed media strategy,

conducted media relations to support

- Flucelvax Quadrivalent filing, approval

- FLUAD filing, VRBAC, approval• Addressed issues -- Italian

Medicines Agency re: suspension of FLUAD, pediatric indication in Argentina, Canada

• Conducted media relations to drive awareness about data presented at Options IX for the Control of Influenza conference

We know healthcareRuder Finn understands what it means to be a patient in need of a better solution. We are the agency that…

9

…educates families and caregivers about breakthrough innovations

for conditions such as MS, cancer and chronic heart failure

…helps people recognize their risk and seek

vaccination for flu and other infectious diseases

…helps patients with diabetes understand new breakthroughs

to transform the way they manage their disease

HERE’S WHAT WE KNOW ABOUT FLUAD

Consumers have mixed thoughts about the flu vaccine

11

Fear of becominginfected with the flu from

the vaccine itself

Deem the flu vaccine unnecessary, especially if

they never had the flu

Concerned about safety, efficacy

ON ONE SIDE… YET, ON THE OTHER…

Will get a flu shot at the suggestion of their doctor

or pharmacist

Are motivated because they fear getting sick

Flu shot has become routine, yet also more

impulse driven

?

Value of flu vaccine understood but becoming less involved in decision-making

12

• Important for overall health and protection against complications

• Fewer HCPs are administering and have little say on stock

• Retail is taking over offering this service

• Concerns over high doses in medications

• Interested in an adjuvanted option as a safer alternative to high dose due to potential greater frequency of side effects

Flu vaccines have become a commodity

13

Pharmacists typically don’t recommend a specific vaccine to their customers…

…and few consumers ask for a certain type and almost none ask for an individual brand, they are more concerned about getting sick from the vaccine and the cost/coverage

…so there is a big opportunity to get those 65+ to ask about the vaccine designed for them—FLUAD

*Hawk Partners Research – Dec. 2014

Older adults and the flu gets coverage;

14

reports on efficacy of last year’s vaccine—can influence decisions about whether or not to get vaccinated

THOSE WHO ARE AT HIGHEST RISK FOR COMPLICATIONS INCLUDE PEOPLE OVER AGE 65 AND CHILDREN AGES 6 MONTHS TO 4 YEARS, NURSING HOME RESIDENTS, AND ADULTS WITH LUNG OR HEART DISEASE.

“ It’s an ongoing and vexing public health problem: People once vigilant about vaccinating their children aren’t nearly as careful about protecting themselves as they age, even though diseases like influenza, pneumonia and shingles (a.k.a. herpes zoster) are particularly dangerous for older people.”

“Every year scientists determine what strains to include in the flu vaccine based on estimates of what strains might be circulating. Some seasons the flu vaccine offers more protection than others. "[The flu vaccine is] not perfect; we wish it were better," said Frieden, adding that getting the vaccine substantially reduces the risk of hospitalization.”

GETTING A FLU SHOT IS THE CORNERSTONE OF PREPAREDNESS. "WE KNOW THAT IT'S NOT A TERRIFIC VACCINE. AT BEST, IT WORKS ABOUT 60% OF THE TIME. HOWEVER, SOMEONE WHO IS VACCINATED AND GETS THE FLU IS LIKELY TO HAVE A LESS SEVERE BOUT, AND A LOWER RISK OF COMPLICATIONS LIKE PNEUMONIA AFTERWARD," SAYS DR. JOHN ROSS, A SPECIALIST IN INFECTIOUS DISEASES AT HARVARD-AFFILIATED BRIGHAM AND WOMEN'S HOSPITAL.”

“

The FLUAD advantage

15

ADJUVANTS enhance the immune response to antigens—prolong stimulus of the immune system

FLUAD has been shown to reduce the incidence of influenza infection and influenza-related hospitalizations in the elderly compared with non-adjuvantedinactivated influenza vaccine

FLUAD elicits a stronger, broader and more persistent immune response in the elderly when compared to non-adjuvanted inactivated influenza vaccines

Competition can tell similar story

16

Associated with a stronger immune response following vaccination

Yet, stakeholders may be WARY OF THE HIGH-DOSE

Results from a clinical trial showed that adults 65 years and older who received the high dose vaccine had

24% fewer influenza infections as compared to those who received the standard dose flu vaccine

OUR CHALLENGEHow can we evolve our story about

FLUAD to make it become something our audience wants and

asks for in their lives?

Our target: the boomers

18

Early Boomers (1946-1954)

Our primary targets who are:• Counterculture Generation• Born Activist – civil rights, women’s rights movements• Inspired by Stand Up for Change reflective of new values• MLK, JFK, Gloria Steinheim• Woodstock, Vietnam, Moonlanding

Late Boomers (1955-1964)

Caretakers of the Early Boomers and our next generation Fluadusers who are:

• Yuppie Generation• Changing traditional family – divorce on rise• Working women• Economic downturn, Oil Embargo, The Pill, Watergate, Iran

Hostage• Live to work

Youthful Outlook on Aging

They are confident & believe in the power of change

Largest online constituency … spending 19 hours a week searching for health & wellness tips. And they love Facebook

Civic minded & believe anything is possibleto make the world

a better place

The first TV generation … watching their favorite old time TV & movies

Savvy shoppers…buying what they want, using credit

Want to feel healthy and young … hitting the gym to exercise

Consumer of healthcare …researching options, working closely with their physician

They are the “Me Generation”

20

Redefining what aging means in our society...

By taking control of their health

They have seen what medicine can do and are open to new possibilities

Something that is tailor-made for their generation ….

To give them the boost they need to protect their health

21

Insert “Add A Boost” Logo

An integrated campaign that empowers individuals to take more control of their health by asking for a flu vaccine specifically designed for them to boost their immune system and provide the

protection they need

Campaign strategic approach

22

Drive asks for FLUAD

Insert “Add A Boost” Logo

Remind 65+ population of the implications of not protecting themselves from the flu as they age

Link the advantages of FLUAD protection by positioning as “designed specifically for the 65+” to boost their health and life

Create greater SOV among the competition in traditional and social media coverage

Brand AwarenessFlu Awareness

HCPs/Pharmacists

PAGs

Influencers(Traditional & Social

Media)

Consumers 65 +

Our Targets

Campaign elements

23

Engage InfluencersInspire Action

Insert Add A Boost logo

Socialize Our Efforts

• Cause-related component with pharmacy partners

• In-store promotions

• “Add a Boost” PSA campaign• National media blitz

Add a Boost FB image

• Facebook program to educate and motivate

• YouTube content distribution• Digital amplification with Outbrain

Add a boost PSA campaign

24

Add a boost PSA campaign• Focuses on empowering individuals to take action & become advocates to “Add A Boost” and be vaccinated

• Feature portraits of individuals who are defying aging and are proactive in managing their health

• Enlists support of “baby boomer” generation personalities now aged 65+ -- Charlie’s Angels, CHiPs, etc.

• Partner with Alliance for Aging Research, American Pharmacists Association or non-traditional partner -BandAid

• PSAs to run on online, television, radio & print

• Two clicks from Fluad website

25

Media blitz-national launch

26

Capitalize on mediability of Charlie’s Angels personalities to discuss healthy aging and to ask for the vaccine that adds a boost to health and life

SMT/RMT targeting TOP 25 DMAS

Appearance on national MORNING

SHOWS

Appearance on national

ENTERTAINMENT SHOWS

Controlled Media VehiclesANRs, MAT RELEASES

65+ HEALTH GENERAL INTERESTONLINE

Adding a boost should be a family affair – get your

elderly parents vaccinated

CAREGIVING

Amplify with long-lead & online media

Your favorite celebs are adding a boost

and getting vaccinated

Add a boost this flu season … go get

vaccinated

Top celebs provide call to action to “Add a Boost”

27

Take the time to learn more about how your immune

system works in tandem with the flu

28

Pharmacy activation

• From September to December, partner with select pharmacies on local activations — Add a Boost Days — within minute clinics areas

• Using pharmacy app — send messages to remind customers to get their vaccines and promote Add a Boost Days

• Feature 10 minute talks/workshops on Adding a Boost to your Life- Self help gurus- Yoga/Tai Chi demonstrations- Beauty suggestions- Good bag includes info on getting influenza after 65+

• Equip pharmacies with tool kits that include Add a Boost:- Signage featuring PSA campaign- Photo filter- Band Aids- Suggestions for talks/workshops- Promotional materials including suggested social posts/byline for newsletters

29

Social media engagement & activation

• Ask people to take a selfie to acknowledge getting the flu shot and encouraging others to get their “boost”

• Launch in conjunction with PSA rollout- Have each of the celebrities Tweet or FB post their selfie to start the call for

pictures

• For each photo posted on Add a Boost Facebook page, Seqiruswill pledge $1 (up to $50,000) to give a boost to advocacy organizations who have shared agendas – e.g., National Association of Area Agencies on Aging, Alliance for Aging Research

• Facebook page will collect gallery of photos and provide a meter for reaching $50,000 pledge goal

30

Social media execution Engagement strategy to elevate campaign awareness & engage stakeholders with educational and emotional messaging

31

Paid promotional strategy targeting audiences through Facebook and YouTube

PHARMACIST & HCP CAMPAIGN

• Send celebrity video postcards using bio targeting on Twitter and email

“SHARE WITH FRIENDS” CHALLENGE

• Distribute PSA online to 65+ via YouTube (20m monthly users 65+) and Facebook

• Tell viewers to challenge friends and family to get the shot together – and forward the PSA to friends and family

ADD A BOOST SOCIAL PROGRAM

• Create platform across Facebook, Twitter and Instagram to house images, posts of inspiration on• The importance of getting vaccinated, and why

an immune boost is important₋ How to talk to the doctor or pharmacist about

the flu vaccine₋ What it feels like to be safe and secure during

flu season• Promote celebrity posts with the question “Get a

boost! I did!”

CONTENT ENGINE FOR FLUAD & RAPIVAB

32

A robust content strategy

33

• Signs, symptoms• Weighing existing

options - what should be used & when?

From a story about XXX

… to the Fluad/Rapivab

Story

• Questions to ask• Peer-to-peer

education• Advocacy-moderated

discussions about PI

• Stories from patients, caregivers, treaters

Content Pillars

Themes

• Administration • Convenience • Clinical benefits

& tolerability

EDUCATION SUPPORT PERSONAL EXPERIENCES VALUE

FLUA RAPIVAB

ADDRESSING THE CHALLENGES TO XXX

Aimed to resonate among all stakeholders and provide a comprehensive value story for FLUAD & RAPIVAB

Keren: Please use same imagery/set up below. I

need to work on this slide

Franchise news engine

34

Cindy to work on News Bureau and include info from slide 33

Media Outreach PHARMACY &

HOSPITALTRADES

Traditional and social media strategy for ongoing news stories about FLUAD & RAPIVAB

Franchise Shipment NEWS ALERT & MNR

Fluad Shipment NEWS ALERT & MNR

CUSTOMIZED & SEASONALSTORY PITCHES

Materials • Press Release(s), MNR• Backgrounders, Infographics,

Videos• Key Messages, Q&A

Analysis• Daily Monitoring• Traditional & Social Media

Tracking • Final Results Reporting

Developing a comprehensive strategic plan for each milestone based on news value and competitive landscape

Our approach to milestone communications

35

Competitive Landscape• FDA/Congress Press

Office Coordination • CI Reports on Key Data• Media Audit

Communications Plan • Overarching Strategy • Tactical Elements • Timeline & Metrics

Third Party Prep• Spokesperson ID• Message Training • Investigator PR Team

Outreach• Advocacy Engagement

Materials • Press Release(s), MNR• Backgrounders,

Infographics, Videos• Key Messages, Q&A

Social Media• Content Strategy• Social

Posts/Calendar• Paid Promotion

Media Engagement• Pre-Briefings• Proactive Pitching to

national, trade, industry, online & broadcast outlets

Internal Communications • Leadership Emails• Employee & Patient Videos• Employee Stories• Infographics

Analysis• Daily Monitoring• Traditional & Social

Media Tracking • Final Results Reporting

Issues preparedness; establish process, manage expectations

36

ReactiveAnalyze scope, impact

ProactiveIdentify, prioritize potential issues

Media monitoring, collect and analyze intelligenceDevelop and implement rapid response plan

Convene US/Global rapid response teams • Medical• Legal• Regulatory• Investor Relations• Marketing• Advocacy• Pharmacovigilance• Corporate

Communications

Develop response materials• Standby statements/

press releases• Q&A• Internal/field

communications

Media-prep for spokespersons

• Internal− Medical− President

• External − Investigators− Patients− Third parties

Plan scenariosIdentify stakeholders• Media • Internal (field, home

office)• HCPs• Patients• Payers• Analysts/shareholders

ABOUT RUDER FINN

Keren: we are handling this section so nothing for you to do

Our mission

38

Strengthen awareness of Rapivab as the IV therapy for influenza in the hospital setting targeting hospital pharmacists, emergency medicine physicians and infectious disease physicians

Cost and familiarity are greatest barriers to Rapivab uptake

39

77%

*Survey results from SERMO online survey conducted from 1/23-2/13

(50%)About 1/3

of the ID specialists indicated that the greatest barrier in prescribing Rapivab is cost, while half

of hospitalists indicated that it is lack of experience with the therapy.

of the ER MEDs reported that the greatest barrier for them in prescribing Rapivab is cost (37%) or lack of experience with the therapy (29%).*

Full course in one dose & compliance is a benefit

40

• Most ER MEDs, ID specialists confident their patients in the ED would benefit from one-dose Rapivab IV infusion

*Survey results from SERMO online survey conducted from 1/23-2/13

• Hospitalists less confident in patient benefit, 60% “not confident”

• ID specialists (46%), ER MEDs (43%), hospitalists (80%), said most important benefit of Rapivab is a full course of treatment in a single dose

• For ID specialists (38%)compliance is key*

Multi-day regimen & GI issues impact compliance

41

About two-fifths of ID specialists (38%), hospitalists (40%) feel that the most common challenge in patients’ experience in complying with an oral antiviral treatment regimen is flu-associated GI issues

*Survey results from SERMO online survey conducted from 1/23-2/13

Over one-third of ER MEDs say the most common challenge is difficulty following a multi-day treatment regimen

2/5

1/3

Rapivab has clear advantages compared to other antiviral therapies used to treat the fluBrief 1-2 lines of copy can go here, brief 1-2 lines of copy can go here.

42

Flu-associated GI issues impact patient compliance

Complex regimen—two inhalations once a day for 10 days

Difficulty following a multi-day treatment regimen—1 dose for 5 days

Patients prone to respiratory distress more often

COLUMN HEADING COLUMN HEADING

Media coverage focuses on industry news and seasonal trends, but there is room for more SOV for RapivabProduct-related coverage highlights differentiating benefits of Rapivab; includes perspectives from HCPs and thought leaders

43

THAT’S A SIGNIFICANT ADVANTAGE WITH PERAMIVIR; WHEN THE PATIENT WALKS OUT OF YOUR EMERGENCY DEPARTMENT, THEY’RE THERAPEUTIC. “DR. FRANK LOVECCHIO, DO, MPH, FACEPVice Chairman of the Department of Emergency Medicine at Maricopa Medical Center, Mar 7, 2017

Peramivir: An Alternative IV Influenza Treatment“That’s a significant advantage with peramivir; when the patient walks out of your emergency department, they’re therapeutic. Whereas with the oral agent [Tamiflu], you have to give one tablet twice daily for 5 days, or 10 total doses, and it’s been well-studied that less than half of patients are compliant with that regimen. Additionally, the oral regimen assumes the patient’s digestive system is intact; that they’re not vomiting and can keep oral medication down. With the 15-minute IV infusion, it doesn’t matter.”

There Might be a Cure for the Flu: Rapivab“Peramivir may be particularly beneficial in the inpatient setting due to its route of administration. Unlike oseltamivir, which is administered orally, and zanamivir, which is inhaled, peramivir is administered intravenously or intramuscularly. Peramivir may be an attractive option in patients with severe influenza who are mechanically ventilated or critically ill…Overall, peramivir appears to be a well-tolerated, convenient alternative in hospitalized influenza patients.”

PERAMIVIR MAY BE AN ATTRACTIVE OPTION IN PATIENTS WITH SEVERE INFLUENZA WHO ARE MECHANICALLY VENTILATED OR CRITICALLY ILL…“JEANNETTE Y. WICK, RPH, MBA, FASCPMar 6, 2017

So, what do we need to get our stakeholders to say…

44

WITH RAPIVAB, I CAN TREAT THE FLU IN JUST ONE DOSE

ER DOCTOR

ONE-DOSE RAPIVAB GUARANTEES COMPLIANCE, GETS PATIENTS

BETTER AND OUT OF THE HOSPITAL

FORMULARY DECISION MAKER

RAPIVAB GUARANTEES PATIENT COMPLIANCE WITH

A FULL COURSE OF TREATMENT,

AND NO GI ISSUES!

INFECTIOUS DISEASE SPECIALIST

RAPIVABOne And Done

45

One And Done… Your obvious choice in flu treatment

EDUCATE & BUILD CHAMPIONS

INFLUENCE FORMULARY DECISION MAKERS

CREATE SURROUND SOUND MEDIA

Online stakeholder education to drive Rapivab value story

Online stakeholder education to drive Rapivab value story

Online stakeholder education to drive Rapivab value story

47

Managing influenza in the hospital

*ExtendMed is a leading information technology company that streamlines the online medical education process

Educating and building champions

Educational Webcast• Recruit target audience:150 per webcast

• Emergency medicine physicians at integrated health systems

• P & T committee members• Easy, mobile friendly registration with

confirmations, reminders and “add to calendar” ensures >60% participation rate

Panel Presentation with Q&A • Professional webcasts with engaging meeting

tools • Secure panel of experts – ER, ID, Man Care;

convene to discuss challenges and solutions in managing flu in the hospital -- trends, gaps, needs

• Outcomes: increase awareness of Rapivabadvantages

Outcomes and Content Extension• Conduct pre- and post-assessments to gauge

learning, input for future event content • Poll participants during meeting • Create social media content, YouTube,

webisodes• Develop podcast series

• Content posted on journal, other dedicated site

• Digital supplements may link to product assets

• Use faculty audio or video modules to strengthen online presence

• Distribute at key meetings

Extend webcast reach through print, digital supplements

Influence the formulary decision makers

Form advisory group of leading formulary decision makers lead by health economist from institution such as Yale, called the One and Done Team

Examine best approach to managing costs of treating influenza in the hospital; create consensus to provide context for Rapivabvalue story:

• Shorter hospital stays, readmissions, relapses

• Lower cost, more efficient triage of patients, quicker recovery compared with other influenza in-hospital treatments

49

One and Done: Optimal Influenza Management in the Hospital

Gather and Analyze Data

• Work with One and Done Team to conduct survey, ask for hospitals to contribute data about their flu treatment experience including cost of using the wrong treatment

• Partner with them to analyze data and develop white paper report

Cascade Findings

• Host virtual roundtable specifically for formulary decision makers

• Announce, expand on report findings

• Amplify report via print and digital supplements targeted to managed care execs

Activate doctor ambassadors for amplification• Provide training for ER and ID doctors to become One and Done ambassadors

• Create One and Done: Optimal Influenza Management in the Hospital toolkit to arm them with messages, tools to approach formulary committee members to make case for Rapivab to improve flu treatment outcomes

• Tool kit to underscore Rapivab value story:− Shorter hospital stays, readmissions, relapses

− Lower cost, more efficient triage of patients, quicker recovery compared with other influenza in-hospital treatments

• Incorporate:− Clinical studies

− Anecdotal/case studies

− Key messages designed especially for doctors

• Make toolkit accessible through ExtendMed

• Roll out through virtual roundtable

50

Leverage value story to guide communications• One-dose Rapivab offers the potential for patients to return to normal function nearly two days

sooner than those who did not receive an antiviral – a benefit particularly important for flu patients who may not be appropriate for treatment with a multi-dose oral antiviral, including those who:

51

– Are unable to take oral medications due to difficulty swallowing or flu-related gastrointestinal sensitivities such as nausea, vomiting or diarrhea

– May have difficulty complying with a multi-dose treatment regimen or would prefer one-dose treatment

– Struggle with inhaled therapies or have pulmonary disease

– Require IV rehydration

• Seqirus provides a number of resources to help ensure that Rapivab is billed for and reimbursed appropriately

Create Media Surround SoundLeverage paid social media amplification

• Share findings from One and Done: Optimal Influenza Management in the Hospital

• Distribute content underscoring speed and simplicity

• Bring real situations to life so practitioners can see benefits they relate to

• Publish op-ed style piece with KOL for paid and earned publication

52

• Benefits of IV solution• Real life testimonials

ID SPECIALISTS ER

• Benefits of IV solution• Real life testimonials• Emphasize speed and completeness

HOSPITAL FORMULARY

• Findings from One and Done white paper• Hospitalist testimonials

53

Create media surround soundLeverage paid social media amplification

• Pump out One and Done: Optimal Influenza Management in the Hospital white paper findings

• Target hospital pharmacists, emergency medicine physicians and infectious disease physicians by using bio targeting on Twitter and LinkedIn

• Talk about speed and simplicity • Bring real situations to life with in vivo situational posts, for example an EMP stating they had a 68 year old patient who came in with influenza and another condition and the first order of business was to quickly get the influenza under control with an IV treatment

Build rapivab brand awareness through cascade of media opportunities

MAR APR MAY JUN JUL AUG SEPT OCT NOV DEC JAN FEB MAR JUN

Rapivab Campaign PlanningMarch – April

Gather champions, build out content,

usher content through reviews, prepare for launch

Educational WebcastsApril - July

Extend webcast with Print, DigitalJune - October

Annual Flu Shipment

Orders PlacedMarch 2017

Panel Presentation with Q & A’s

June

2017-2018 Flu Season

Annual Flu Shipment

July-August

Flu Season Campaign: SMT/RMT, ANR, Mat Release,

Media Blitz

Study Examining the Cost on Hospitals Gather Real-Time Data Throughout the Season

Sept – Jan

Analyze study outcomes

Plan to publish initial

results in time for 2018

orde4

54

ACIP MeetingJune 20-21

ACIP MeetingFeb 21-22

National Influenza Vaccination Week

December 6-12

Education Content – Outcomes & Expansion: Assessments, Social Media, Podcast Series

Continued Surround Sound Media Outreach

ACIP MeetingJune 21-

22

ACIP MeetingOct 25-26

Options IX Congress

Other MilestonesCampaign MilestonesPublication / Medical Meeting